The sector is defensive, and biopharmaceuticals have, for the most part, limited tariff and transfer price exposure, he ...

During the fourth quarter, the Harbor Health Care ETF returned –10.89%, underperforming the Russell 3000 Growth Health Care ...

Burdened by continuing troublesome inflation and cuts to federal health agencies, health care sector stocks are barely treading water. The S&P 500 Health Care Sector Index was fla ...

Therefore, the biotech sector is not suitable for everyone ... even if the stock price rises in the currency of origin. Any performance statistics that do not adjust for exchange rate changes ...

"China's biotechnology sector thrives on a dual engine — Beijing's constellation ... pharmaceutical giants stems partly from the remarkable global market performance of its homegrown innovative drugs.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison. Important Information Please note the value of investments ...

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison. Important Information Please note the value of investments ...

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

LONDON (Reuters) -Trump administration cuts across federal health agencies have sent shivers through a biotech industry ...

According to analysts at Jefferies, legislation such as the newly proposed bills that aim to streamline regulatory processes ...